PharmaTimesNews & Politicsnews

Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma

Tuesday, June 9, 2026John PinchingView original

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

Read the full article on the original site.